SLC5A2 and glomerulonephritis: Among a retrospective, observational cohort of four-hundred and ninety-three adult glomerulonephritis patients already on RAS inhibition, treatment with SGLT2 inhibition resulted in reductions of proteinuria of 35%, 41%, 45%, and 48% at 3,6,9 and 12 months of treatment.